$20.51
-0.48-2.29%
Last update: 9:02 AM
15 minutes delayed
Trxade Health
MEDSNASDAQ
Trxade Health (NASDAQ:MEDS) Stock, Analyst Ratings, Price Targets, Forecasts
Trxade Health Inc has a consensus price target of $1.42 based on the ratings of 3 analysts. The high is $1.75 issued by Maxim Group on March 28, 2023. The low is $1.25 issued by EF Hutton on June 1, 2023. The 3 most-recent analyst ratings were released by EF Hutton, EF Hutton, and Maxim Group on June 1, 2023, May 16, 2023, and March 28, 2023, respectively. With an average price target of $1.42 between EF Hutton, EF Hutton, and Maxim Group, there's an implied -93.09% downside for Trxade Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
EF Hutton
EF Hutton
Maxim Group
1calculated from analyst ratings
Analyst Ratings for Trxade Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/01/2023 | Buy Now | -93.91% | EF Hutton | Fozia Ahmed | → $18.75 | Assumes | → Buy | Get Alert |
| 05/16/2023 | Buy Now | -93.91% | EF Hutton | Constantine Davides | $25.5 → $18.75 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | -91.47% | Maxim Group | Allen Klee | $37.5 → $26.25 | Maintains | Buy | Get Alert |
| 12/09/2021 | Buy Now | -78.06% | EF Hutton | Constantine Davides | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Trxade Health (MEDS) stock?
The latest price target for Trxade Health (NASDAQ:MEDS) was reported by EF Hutton on June 1, 2023. The analyst firm set a price target for $1.25 expecting MEDS to fall to within 12 months (a possible -93.91% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Trxade Health (MEDS)?
The latest analyst rating for Trxade Health (NASDAQ:MEDS) was provided by EF Hutton, and Trxade Health their buy rating.
When was the last upgrade for Trxade Health (MEDS)?
There is no last upgrade for Trxade Health
When was the last downgrade for Trxade Health (MEDS)?
There is no last downgrade for Trxade Health.
When is the next analyst rating going to be posted or updated for Trxade Health (MEDS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trxade Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trxade Health was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.
Is the Analyst Rating Trxade Health (MEDS) correct?
While ratings are subjective and will change, the latest Trxade Health (MEDS) rating was a with a price target of $0.00 to $1.25. The current price Trxade Health (MEDS) is trading at is $20.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.